Proteome signs biomarker deal with Takeda

Licensing

Proteome Sciences plc of Cobham, UK, has announced that the Japanese pharmaceutical company Takeda has signed a contract to use Proteome’s PS Biomarker Services for a preclinical study.

Proteome specialises in the discovery and validation of biomarkers and rapid assay development in neurodegenerative diseases and cancer. Its PS Biomarker Services use its proprietary Tandem Mass Tags technology and reference materials, combined with isotope dilution mass spectrometry.

The company’s own research is focused on neurological and neurodegenerative conditions, and it has discovered and patented blood biomarkers in stroke and brain damage as well as several cancers, solid organ transplant rejection and Alzheimer’s disease.